These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 23103819)

  • 21. Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab.
    Verma HD; Scherl EJ; Jacob VE; Bosworth BP
    J Dig Dis; 2011 Oct; 12(5):379-83. PubMed ID: 21955431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
    Casanova MJ; Chaparro M; Domènech E; Barreiro-de Acosta M; Bermejo F; Iglesias E; Gomollón F; Rodrigo L; Calvet X; Esteve M; García-Planella E; García-López S; Taxonera C; Calvo M; López M; Ginard D; Gómez-García M; Garrido E; Pérez-Calle JL; Beltrán B; Piqueras M; Saro C; Botella B; Dueñas C; Ponferrada A; Mañosa M; García-Sánchez V; Maté J; Gisbert JP
    Am J Gastroenterol; 2013 Mar; 108(3):433-40. PubMed ID: 23318480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
    Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
    Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery.
    Kane S; Ford J; Cohen R; Wagner C
    J Clin Gastroenterol; 2009 Aug; 43(7):613-6. PubMed ID: 19142167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.
    Moens A; van der Woude CJ; Julsgaard M; Humblet E; Sheridan J; Baumgart DC; Gilletta De Saint-Joseph C; Nancey S; Rahier JF; Bossuyt P; Cremer A; Dewit S; Eriksson C; Hoentjen F; Krause T; Louis E; Macken E; Milenkovic Z; Nijs J; Posen A; Van Hootegem A; Van Moerkercke W; Vermeire S; Bar-Gil Shitrit A; Ferrante M
    Aliment Pharmacol Ther; 2020 Jan; 51(1):129-138. PubMed ID: 31692017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice survey.
    Oussalah A; Roblin X; Laharie D; Filippi J; Flamant M; Faure P; Phelip JM; Bigard MA; Peyrin-Biroulet L
    Aliment Pharmacol Ther; 2009 Oct; 30(8):854-63. PubMed ID: 19764940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
    Trinder MW; Lawrance IC
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis.
    Kiely CJ; Subramaniam K; Platten J; Pavli P
    Intern Med J; 2016 May; 46(5):616-9. PubMed ID: 27170239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease.
    Gisbert JP; Chaparro M
    Am J Gastroenterol; 2013 Sep; 108(9):1426-38. PubMed ID: 23752881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.
    Leung Y; Panaccione R; Ghosh S; Seow CH
    Can J Gastroenterol Hepatol; 2014 Oct; 28(9):505-9. PubMed ID: 25101334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2007 Apr; 46(4):695-8. PubMed ID: 17158212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
    Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
    Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease.
    Kotlyar DS; Osterman MT; Diamond RH; Porter D; Blonski WC; Wasik M; Sampat S; Mendizabal M; Lin MV; Lichtenstein GR
    Clin Gastroenterol Hepatol; 2011 Jan; 9(1):36-41.e1. PubMed ID: 20888436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Biological therapy in women with inflammatory bowel disease during pregnancy].
    Koželuhová J; Balihar K; Janská E; Fremundová L; Matějovič M
    Vnitr Lek; 2014; 60(7-8):630-4. PubMed ID: 25130641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
    Gniadecki R; Kragballe K; Dam TN; Skov L
    Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.